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Understanding Fragmentation of Prostate
Cancer Survivorship Care
Implications for Cost and Quality
Ted A. Skolarus, MD, MPH1,2; Yun Zhang, PhD2; and Brent K. Hollenbeck, MD, MS1,2
BACKGROUND: Cancer survivors are particularly prone to the effects of a fragmented health care delivery system.
The implications of fragmented cancer care across providers likely include greater spending and worse quality of
care. For this reason, the authors measured relations between increasing fragmentation of cancer care, expenditures,
and quality of care among prostate cancer survivors. METHODS: A total of 67,736 patients diagnosed with prostate
cancer between 1992 and 2005 were identified using Surveillance, Epidemiology, and End Results (SEER)-Medicare
data. Using the Herfindahl-Hirschman Index and a measure of the average number of prostate cancer providers over
time, patients were sorted into 3 fragmentation groups (low, intermediate, and high). The authors then examined an-
nual per capita survivorship expenditures and a measure of quality (ie, repetitive prostate-specific antigen [PSA] test-
ing within 30 days) according to their fragmentation exposure using multinomial logistic regression. RESULTS:
Patients with highly fragmented cancer care tended to be younger, white, and of higher socioeconomic status (all
P < .001). Prostate cancer survivorship interventions were most common among patients with the highest fragmenta-
tion of care across providers (P < .001). After adjustment for clinical characteristics and prostate cancer survivorship
interventions, higher degrees of fragmentation continued to be associated with repetitive PSA testing (13.6% for high
vs 7.0% for low fragmentation; P < .001) and greater spending, particularly among patients not treated with androgen
deprivation therapy. CONCLUSIONS: Fragmented prostate cancer survivorship care is expensive and associated with
potentially unnecessary services. Efforts to improve care coordination via current policy initiatives, electronic medical
records, and the implementation of cancer survivorship tools may help to decrease fragmentation of care and
mitigate downstream consequences for prostate cancer survivors. Cancer 2012;118:2837-45. VC 2011 American Cancer
Society.
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INTRODUCTION
Fragmented health care fosters spending growth and compromises the quality of care.1-4 As a result of poor care
coordination, care fragmented among providers may manifest in the form of redundant services, decreased patient satisfac-
tion, and even worse health outcomes.5-7 Eliminating redundant testing, a potential by-product of fragmentation, could
save the US health care system up to $8 billion annually.8 Because of the complexity of cancer care, the implications of
fragmented delivery may be exacerbated and fuel health care spending for patients, providers, and payers. Remedies for
fragmentation focus on improving care coordination via electronic medical records9 and better care planning,10 with the
hope of mitigating its consequences. For these reasons, efforts to improve the coordination of care are centerpieces of cur-
rent health policy initiatives (eg, medical homes).10-12
Because there are over 2 million prostate cancer survivors, accounting for nearly $7 billion in annual spending, mini-
mizing the fragmentation of care for these men has significant cost and quality implications.13,14 In fact, prostate cancer
survivors may be particularly prone to the effects of cancer care that is fragmented across providers. The variety of initial
treatments, their long-term side effects (eg, incontinence and impotence), subsequent prostate cancer survivorship inter-
ventions (eg, androgen deprivation therapy [ADT]), and a prolonged natural history predispose survivors to fragmented
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cancer care.15 In addition, having multiple providers (eg,
urologists, radiation and medical oncologists, and primary
care providers) with fluctuating roles renders patients sus-
ceptible to the downstream consequences of fragmenta-
tion,16,17 the implications of which likely include greater
spending for cancer care and worse quality of care.
In light of the prevalence, cost, and protracted clini-
cal course of prostate cancer, we performed a study to bet-
ter understand fragmented cancer survivorship care. We
first quantified the degree of fragmentation of prostate
cancer care across providers and characterized clinical
characteristics and prostate cancer survivorship interven-
tions associated with increasing fragmentation. Next, we
assessed the degree to which increasing fragmentation of
cancer care across providers was associated with greater




We used Surveillance, Epidemiology, and End Results
(SEER)-Medicare data for the years 1992 through 2005
to identify patients with prostate cancer (n ¼ 423,908).
The SEER-Medicare data combine population-based can-
cer registry data with the ability to perform longitudinal
follow-up using Medicare claims.18 For this study, we
identified all Medicare patients ages 66 to 99 years who
were at least 1 year removed from a diagnosis of prostate
cancer (n ¼ 79,826), as described in our prior work.19
Because the initial treatment phase of prostate cancer may
necessarily involve many different providers, we chose to
examine the subsequent period to capture the effects of
fragmentation during the protracted survivorship (ie, con-
tinuing care) phase of prostate cancer care. To ensure
comparability of secular and geographic reimbursement
trends over the study period, we limited this study to those
patients diagnosed in the SEER 13 registries.20 Patients in
the fee-for-service program who were eligible for Medi-
care Parts A and B and did not participate in managed
care were included. Moreover, the minority of patients
without office visits associated with a prostate cancer diag-
nosis during survivorship were excluded. We observed
patients until December 31, 2005 or until the beginning
of the last year of life, whichever occurred first. Using
these criteria, our study population was comprised of
67,736 patients who were followed through December
31, 2005.
Measures of Fragmentation
An ideal measure of fragmentation or the potential for
poor care coordination would capture the intensity of care
within individual providers, as well as account for the
breadth of care across providers, for a specific disease in a
patient over time. We expect greater fragmentation of
care among cancer survivors after their initial treatment
(eg, care distributed across a greater number of providers)
is associated with worse quality and greater survivorship
expenditures. Unfortunately, to the best of our knowl-
edge, there is no ideal single measure to account for these
effects and therefore we operationalized fragmentation in
2 ways, as described below.
Average Number of Prostate Cancer
Providers
Because an increasing number of prostate cancer providers
after initial treatment fosters fragmented care, we enumer-
ated the average number of prostate cancer providers per
patient during the survivorship period. Clinical scenarios
involving an average number of providers are illustrated
in Figure 1. In Example 1, a single urologist is responsible
for all prostate cancer-related care during the survivorship
period. This would represent the least fragmented care,
with the average number of providers equal to 1, and
accounts for the duration of the survivorship period. In
Figure 1. Various examples of fragmentation and prostate
cancer survivorship care are shown. In Example 1, a single
urologist is responsible for all prostate cancer-related claims
during the survivorship period. This would represent the least
fragmented care and the average number of providers would
equal 1. In contrast, Example 4 represents a patient with mul-
tiple providers involved in his prostate cancer care for the
entire survivorship period. This situation might represent the
greatest potential for the consequences of fragmented can-
cer care (average number of providers: 4).
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contrast, Example 4 represents a patient with multiple
providers involved in his prostate cancer care for the entire
survivorship period. This situation represents the greatest
potential for fragmented prostate cancer care (average
number of providers: 4).
We calculated this measure in 3 steps to adjust for
the duration of each patient’s survivorship period. First,
we identified all services with a primary diagnosis of pros-
tate cancer (International Classification of Diseases [ICD]
code 185 [prostate cancer]) for each patient in the carrier
files. Each claim was assigned to a provider using a unique
provider identification number. Second, we assigned a
date for each provider’s first and last claim to determine
their coverage period within each patient’s claims. If a
substantial period of time had passed without a provider’s
involvement in a given patient’s care (ie, no service claim
for a period of > 1.5 years), these claims were treated as a
solitary coverage date, with the same start and end dates.
Third, we enumerated the total number of provider days
of coverage for each patient during the survivorship pe-
riod. This number was then divided by the entire duration
of the survivorship period for each patient to determine
the average number of providers over time.
This measure has clinical relevance and is relatively
simple to calculate; however, it may fall short in some
cases because it does not account for the intensity of
patient care by a given provider. For example, multiple
prostate cancer providers may be involved in a survivor’s
care, yet the majority of visits might be with a single pro-
vider (eg, urologist) who coordinates their care, thereby
limiting the effects of fragmentation (Fig. 1).
Concentration of Prostate Cancer
Survivorship Care
To address the intensity of prostate cancer care across pro-
viders, we used the Herfindahl-Hirschman Index (HHI).
The HHI is a commonly used instrument in the field of
economics to measure market share, or the concentration
of goods and services provided in a market among various
firms.21-24 In the same manner, we used the HHI to mea-
sure the ‘‘market share,’’ or concentration of office visits,
for prostate cancer care among a survivor’s providers. To
calculate this measure, the percentage of each patient’s
office visits for prostate cancer care was determined for
each provider using unique provider identifiers. Next, we
summed the squares of the percentages of prostate cancer
office visits (ie, the share) provided by each provider. For
example, less concentrated office visits dispersed across
providers might correspond to an HHI of 0.42 (urology:
20% [0.22 ¼ 0.04], radiation oncology: 60% [0.62 ¼
0.36], medical oncology: 10% [0.12¼ 0.01], and primary
care: 10% [0.12 ¼ 0.01] ¼ [0.04 þ 0.36 þ 0.01 þ
0.01]), whereas concentration within a solitary provider
would correspond to an HHI of 1.0 (urology: 100% [1.02
¼ 1.0]). This measure of fragmentation is relatively sim-
ple to calculate and identifies the degree of concentration
of prostate cancer care within providers. However, it does
not account for the changes over time captured with the
average number of providers.
For the current study, we posited a priori that
greater fragmentation (ie, a greater average number of
providers and less concentrated care, or lower HHI)
would be associated with increased cost and potentially
decreased quality of prostate cancer survivorship care. For
this reason, we categorized fragmentation into 3 groups
using a combination of both measures: low (< 50th per-
centile average number of providers and> 50th percentile
HHI), intermediate (> 50th percentile average number of
providers and > 50th percentile HHI or < 50th percen-
tile average number of providers and < 50th percentile
HHI), and high (> 50th percentile average number of
providers and< 50th percentile HHI).
Outcomes
Our primary outcome was annual per capita survivorship
expenditures for prostate cancer care, assessed through
December 31, 2005. All corresponding expenditures asso-
ciated with a primary diagnosis of prostate cancer (ICD-9
code 185 [prostate cancer]) were tallied within the inpa-
tient, outpatient, and carrier files until the end of the
study period (December 31, 2005) or until the beginning
of the last year of life, whichever occurred first. We specifi-
cally excluded all end-of-life spending (within 1 year of
death). We used the methodology described by Brown et
al to measure annual per capita survivorship (ie, continu-
ing care phase) expenditures.20 Payments were standar-
dized to 2005 dollars using the Hospital Input Price
Index for Medicare Part A25 and the Medicare Economic
Index for Medicare Part B claims26 to account for changes
in health care input price inflation. The geographic differ-
ences in Medicare payments were also adjusted for using
the Capital Geographic Adjustment Factor for Medicare
Part A25 and the Geographic Practice Cost Index for
Medicare Part B claims.27
Because interventions during prostate cancer survi-
vorship are not uncommon28 and may serve as a measure
of patient complexity that might warrant the involvement
of multiple providers and increase spending, we also
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examined the use of prostate cancer survivorship interven-
tions across fragmentation groups. These included ADT,
radiotherapy, chemotherapy, cystoscopic procedures, and
placement of artificial urinary sphincters and penile pros-
theses during the survivorship period. We used the appro-
priate Healthcare Common Procedure Coding System
(HCPCS) codes in the carrier and outpatient files to
determine whether each patient had a claim for any of
these interventions, regardless of the associated diagnosis,
during the survivorship period.
As a secondary outcome, we measured the effects of
fragmented prostate cancer care on quality. Because repet-
itive (ie, redundant) testing is usually unnecessary, it may
represent suboptimal quality of care. For this reason, we
chose repeat PSA testing within 30 days among prostate
cancer survivors at least 1 year removed from diagnosis as
our measure of repetitive care (yes/no). Although there
may be some clinical scenarios that might require this, we
posited that increasing fragmentation of cancer care
would be associated with the greater potential for repeti-
tive testing even after adjustment for clinical characteris-
tics, disease severity, and prostate cancer survivorship
interventions. At least 2 PSA claims during survivorship
were necessary to determine this measure (n ¼ 33,447
patients). We used the appropriate HCPCS codes in the
carrier files to determine the frequency of repeat PSA
testing.
Statistical Analysis
First, we examined differences in the clinical characteris-
tics of patients across our measure of fragmentation (low,
intermediate, and high) using the Mantel-Haenszel chi-
square test. Patients were categorized according to age
(ages 66-69 years, then in 5-year intervals thereafter), race
(white, black, and other), socioeconomic status, comor-
bidity, tumor grade (low, medium, high, and unknown),
tumor stage (local/regional, distant, and unstaged), rural
status, initial treatment, and prostate cancer survivorship
interventions. To measure comorbidity, Medicare claims
made 12 months before a diagnosis of prostate cancer
were evaluated using the methods described by Klabunde
et al.29 We used the approach of Diez Roux et al to ascer-
tain socioeconomic status at the level of the patient’s ZIP
code.30 Any missing values for these variables were coded
as unknown. We categorized each patient’s initial treat-
ment (within 1 year of diagnosis) using appropriate proce-
dure codes (ICD-9 and HCPCS codes).
Next, we compared the annual per capita survivor-
ship expenditures according to our fragmentation expo-
sure using the analysis of variance test. We used the
Mantel-Haenszel chi-square test to compare the percent-
age of patients with repetitive PSA tests across our frag-
mentation categories. We then rank-ordered and sorted
annual per capita survivorship expenditures into 3 groups:
low, intermediate, and high. Finally, we used multinomial
logistic regression models to examine whether fragmenta-
tion was associated with low, intermediate, and high an-
nual per capita survivorship expenditures and worse
quality of survivorship care in terms of repetitive PSA
within 30 days. Each of the models was adjusted for the
covariates described above (age, race, comorbidity, socioe-
conomic status, rural status, tumor grade, tumor stage,
initial treatment, and prostate cancer survivorship inter-
ventions). The adjusted models were then used to predict
how our cost and quality outcomes varied according to
the degree of fragmentation. Because of its overbearing
effect on the cost of survivorship care, we also stratified
patients by whether they had received ADT injections
during survivorship in our cost models.
All analyses were performed using computerized
software (SAS 9.2, SAS Institute Inc, Cary, NC; R Ver-
sion 2.9) and all testing was 2-sided. The probability of a
type I error was set at 0.05. The University of Michigan
Institutional Review Board approved the study protocol.
RESULTS
As shown in Table 1, patients with highly fragmented
prostate cancer care tended to be younger, white, of higher
socioeconomic status (all P< .001) and were observed for
longer intervals (high fragmentation, median of 64.7
months; intermediate fragmentation, median of 57.3
months; and low fragmentation, median of 39.6 months).
In terms of initial treatment, fragmentation was more
common among patients undergoing radiotherapy. For
example, a greater percentage of patients with the most
fragmented care underwent radiotherapy as their initial
treatment compared with patients with the least frag-
mented care (44.4% for high fragmentation vs 32.2% for
low fragmentation; P < .001). Moreover, greater frag-
mentation care was also associated with the increased use
of prostate cancer survivorship interventions (P < .001),
including cystoscopic procedures (38.2% for high frag-
mentation vs 22.6% for low fragmentation) and ADT
(49.8% for high fragmentation vs 34.2% for low
fragmentation).
As fragmentation of prostate cancer survivorship
care increased, so did unadjusted annual survivorship
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expenditures. Annual, unadjusted, per capita expenditures
for prostate cancer survivorship care were> 3-fold higher
among patients with the most fragmented care compared
with those with the least fragmented care (median annual
per capita expenditures, $453 for high fragmentation vs
$142 for low fragmentation; P< .001) (Table 2). In addi-
tion, fragmented care was associated with higher unad-
justed rates of repetitive PSA testing (14.7% for high
fragmentation vs 5.7% for low fragmentation; P < .001)
(Table 2).
Table 1. Patient and Disease Characteristics According to the Degree of Fragmented Survivorship
Care
Characteristic Fragmentation of Care P
Low Intermediate High
No. of patients 25,405 18,115 24,216
Median follow-up, mo 39.6 57.3 64.7
Age, % <.001
66-69 y 23.6 23.8 25.8
70-74 y 30.1 33.1 35.6
75-79 y 25.4 26.2 25.1
80-84 y 14.3 12.1 10.2
‡85 6.6 4.8 3.3
Race, % <.001
White 70.1 74.6 75.2
Black 4.7 6.8 8.3
Other/unknown 25.2 18.6 16.5
Socioeconomic status, % <.001
Low 24.1 26.1 25.5
Medium 29.6 30.3 30.9
High 25.2 30.0 33.6
Unknown 21.1 13.6 10.0
Rural, % 1.9 1.4 1.4 <.001
Comorbidity, % <.001
0 81.4 81.3 82.0
1 13.1 13.5 13.5
2 3.7 3.5 3.2
‡3 1.8 1.7 1.3
Tumor grade, % <.001
Well differentiated 8.9 8.6 8.2
Moderately differentiated 51.0 55.2 56.3
Poorly differentiated 15.7 18.5 21.5
Unknown 24.4 17.7 14.0
Tumor stage, % <.001
Localized/regional 70.5 76.9 87.2
Distant 2.4 2.6 3.1
Unknown 27.1 20.5 9.7
Initial treatment, % <.001
Observation 21.4 19.1 18.4
Surgery 23.1 19.8 17.1
Radiotherapy 32.2 39.5 44.4
Surgery and radiotherapy 0.9 1.7 1.9
ADT 22.4 19.9 18.2
Prostate cancer survivorship interventions, % <.001
ADT 34.2 43.6 49.8
Radiotherapy 3.4 7.4 17.2
Chemotherapy 17.3 22.7 25.6
Cystoscopic procedures 22.6 31.7 38.2
Artificial urinary sphincter 0.8 1.2 1.2
Penile prosthesis 2.2 3.2 3.7
Abbreviation: ADT, androgen deprivation therapy.
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After adjusting for measured patient and disease
characteristics as well as the use of prostate cancer survi-
vorship interventions, higher degrees of fragmentation
were associated with more repetitive PSA testing within
30 days and greater survivorship spending in some cases
(Figs. 2A and 2B) (Table 3). Compared with patients
with the highest degree of fragmented care, patients with
the least fragmented care were nearly half as likely to
undergo repetitive PSA testing within 30 days (13.6% re-
petitive PSA testing in those with high fragmentation vs
7.0% repetitive PSA testing in those with low fragmenta-
tion). Although increasing fragmentation of care was asso-
ciated with increased annual spending among patients
who were not treated with ADT injections, the relation
did not persist when examining patients who were treated
with ADT injections. For example, among those not
receiving ADT, 5.5% of survivors with the highest degree
of fragmented care would be expected in the highest
spending group compared with 2.3% in the least frag-
mented group when adjusted for age, race, comorbidity,
socioeconomic status, rural status, tumor grade, tumor
stage, initial treatment, and prostate cancer survivorship
interventions. Not surprisingly, patients treated with
ADT during survivorship had greater annual prostate can-
cer expenditures. However, the relations between frag-
mentation and spending were found to be less direct
among this group of survivors, in which 8.0% of patients
in the least fragmented group, 9.1% of those in the inter-
mediate fragmentation group, and 8.7% of patients in the
high fragmentation group would be predicted to be high-
cost survivors.
We also performed a sensitivity analysis to examine
whether using concentration of prostate cancer survivor-
ship care (HHI) as our measure of fragmentation would
produce similar findings. We sorted patients into 3 frag-
mentation groups according to their HHI. After adjust-
ment, the results again indicated that higher degrees of
fragmentation (ie, a lower HHI) were associated with
more repetitive PSA testing within 30 days and greater
survivorship spending among patients not receiving ADT
Table 2. Unadjusted Annual Prostate Cancer Survivorship Spending and Repetitive PSA Testing According to the Degree of
Fragmented Care
Unadjusted Quality and Cost Measures Fragmentation of Care P
Low Intermediate High
Repetitive PSA testing within 30 d, % of patients 5.7% 9.2% 14.7% <.001
Annual per capita survivorship expenditures (2005 dollars, median) $142 $228 $453 <.001
Abbreviation: PSA, prostate-specific antigen.
Figure 2. Relationship between degree of fragmentation,
(A) survivorship spending, stratified by whether patients
underwent androgen deprivation injection therapy (ADT),
and (B) repetitive prostate-specific antigen (PSA) testing.
Patients with higher fragmentation of care were more likely
to undergo repetitive PSA testing within 30 days, independ-
ent of clinical characteristics and prostate cancer survivorship
interventions (P < .05 for all comparison groups). In addition,
patients with higher fragmentation of care who were not
treated with ADT were more likely to have greater annual
spending. For example, among those not receiving ADT, 5.5%
of survivors with the highest degree of fragmented care
would be in the highest spending group compared with 2.3%
in the least fragmented group (adjusted for age, race, comor-
bidity, socioeconomic status, rural status, tumor grade, tumor
stage, initial treatment, and prostate cancer survivorship
interventions).
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injections, which was similar to our primary analysis. The
relation between fragmentation and annual spending
among patients treated with ADT injections suggested
negligible differences (approximately 1%) in the probabil-
ity of being a high-cost survivor among the HHI groups.
DISCUSSION
Fragmented prostate cancer survivorship care is expensive
and is associated with potentially unnecessary services.
Among prostate cancer survivors, highly fragmented care
was > 3 times more costly than the least fragmented care
due, in part, to the greater use of prostate cancer survivor-
ship interventions. As fragmentation of cancer care
increased, spending also increased independent of clinical
characteristics and the use of survivorship interventions,
particularly among patients not treated with ADT. In rel-
ative terms, repetitive PSA testing within 30 days was also
more common with higher levels of fragmentation. With
> 2 million prostate cancer survivors, the cost and quality
implications of fragmentation are nontrivial. Efforts to
improve care coordination via current policy initiatives,
electronic medical records, and the implementation of
cancer survivorship tools may help decrease fragmentation
of care and mitigate its downstream consequences for
prostate cancer survivors.
As demonstrated in the current study, cancer
patients subjected to fragmented care are at risk for worse
quality of care as measured by repetitive PSA testing.
Communication breakdowns may lead to unnecessary
venipunctures, additional uncertainty surrounding PSA
levels,31 and even compromise patients’ confidence in
their providers.32 There are at least 2 scenarios in which
intense PSA testing among prostate cancer survivors
might occur. First, a lack of care coordination could
prompt PSA tests from different providers (ie, redundant
testing). Different providers may also use different PSA
assays, resulting in clinically insignificant differences in
PSA values33 that prompt patient anxiety and further test-
ing and health care use. This may be particularly true for
patients undergoing radiotherapy, the initial treatment
found to be most prone to fragmented care in the current
study. These survivors have both urologists and radiation
oncologists to contend with, making adequate role identi-
fication and the coordination of care essential for the effi-
cient delivery of survivorship care. Second, concerns
about disease recurrence or progression may drive such a
phenomenon. Better understanding of the value of inten-
sive PSA surveillance to detect and guide treatment for
biochemical disease recurrence and metastatic disease is
warranted. However, even after adjustment for the receipt
of ADT, we observed intense PSA testing patterns with
increasing fragmentation of care, suggesting redundancy.
Such PSA testing may have associated opportunity costs
for providers who are ultimately responsible for the results
and for patients subjected to additional visits and test-
ing.34 Perhaps more consolidation of care and better
delineation of provider roles after initial treatment are
Table 3. Adjusted Probability of Annual Prostate Cancer Survivorship Spending and Repetitive PSA
Testing According to the Degree of Fragmented Carea




Adjusted probability of repetitive PSA testing
within 30 d, % of patients
7.0 9.6 13.6
Annual prostate cancer survivorship spend-
ing among patients with no ADT during
survivorship, % of patients
Low cost (<$1179) 96.0 93.2 89.6
Intermediate cost ($1179-$2351) 1.7 2.7 4.9
High cost (>$2351) 2.3 4.1 5.5
Annual prostate cancer survivorship spend-
ing among patients treated with ADT dur-
ing survivorship, % of patients
Low cost (<$3178) 69.5 66.4 69.9
Intermediate cost ($3178-$6326) 22.5 24.5 21.4
High cost (>$6326) 8.0 9.1 8.7
Abbreviations: ADT, androgen deprivation therapy; PSA, prostate-specific antigen.
a Adjusted for age, race, comorbidity, socioeconomic status, rural status, tumor grade, tumor stage, initial treatment, and
prostate cancer survivorship interventions.
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necessary to decrease fragmentation of prostate cancer
care, regardless of disease recurrence and even in the set-
ting of metastatic disease. Moreover, the Institute of Med-
icine35 and the 2004 President’s Cancer Panel36 proposed
prostate cancer survivorship care plans and guidelines as
tools with which to improve the delivery of cancer care.
Most studies agree that poor coordination of care
(ie, fragmentation) is associated with worse quality in
terms of patient satisfaction and outcomes for chronic dis-
ease.3-7,32 In fact, the medical home model and accounta-
ble care organizations are both current health reform
efforts to improve the coordination of chronic disease
care.3,4,6,10-12 One obstacle facing improvements in care
coordination, at least in terms of cancer care, is a lack of
clearly defined roles for the surgeons, radiation and medi-
cal oncologists, and primary care providers caring for can-
cer survivors.15 Specialty and primary care organizations
might be well served to define provider roles and responsi-
bilities over the disease course so that patients have a con-
sistent message regarding who is in charge of their care.
Electronic medical records and integrated delivery sys-
tems, as in the Veterans Affairs and Kaiser Permanente
systems, may also hasten improvements in the coordina-
tion of care by enabling increased communication and
providing guidance to providers of prostate cancer and
other chronic disease care.37,38
Several considerations should be noted when inter-
preting the results of the current study. First, we were only
able to account for measured patient and disease charac-
teristics in our models. Significant selection bias (ie,
unmeasured confounding) may exist such that more com-
plicated patients received more treatment, were more ex-
pensive, and necessarily had more fragmented care.
However, there were minimal differences noted with
regard to measured comorbidity burden across the frag-
mentation groups, thereby lowering our suspicion of sig-
nificant unmeasured differences in health status. We also
took prostate cancer survivorship interventions into con-
sideration in our models and interpretation of the results
to account for patient complexity and possible referral
bias. In some cases, complicated prostate cancer patients
might need to see different specialists (ie, less concentrated
care) to obtain the best quality of care. This may or may
not be true for patients with ongoing treatment-related
side effects and recurrent disease. However, repetitive PSA
testing and spending (at least among patients not treated
with ADT) increased with increasing fragmentation of
cancer care, even after adjustment. In addition, all patients
were at least 1 year removed from their diagnosis so the
acute side effects (eg, incontinence) from primary inter-
ventions should have stabilized, thereby decreasing the
need for fragmented care among multiple providers for
the majority of patients. Being aware that the potential for
poor care coordination and the consequences of frag-
mented care increase with patient complexity may guide
future efforts to better coordinate prostate cancer care.
Second, patients included the current study were aged
> 66 years and experienced decreased fragmentation of
prostate cancer care with increasing age. However, > 33%
of men with newly diagnosed prostate cancer are aged< 65
years.13 The cost and quality implications of fragmented
cancer care are likely greater for these men given their longer
life expectancy and increased exposure tomultiple providers.
Third, to understand whether fragmentation of care relied
solely on the concentration of care among providers, we per-
formed a sensitivity analysis using the HHI. Although we
discovered similar trends, because of the limitations of this
approach with respect to time spent in survivorship and the
number of providers as we describe above, we pursued the
composite measure of fragmentation. Moreover, although
our cost outcomes for patients not treated with ADT were
consistent in the primary and sensitivity analyses, there did
not appear to be a clear relation between fragmentation and
annual spending for the more expensive survivors who were
treated with ADT injections (Fig. 2). One explanation
might be that the magnitude of spending for ADT masks
the effects of fragmentation on annual prostate cancer survi-
vorship expenditures. Further study is needed to understand
the limitations and validity of these measures of fragmented
health care delivery and their downstream implications.
Last, it is unclear how fragmented care across specialties
rather than providers as in this study may be associated with
our prostate cancer survivorship outcomes. Further efforts
are needed examining provider-, specialty-, and system-level
fragmentation effects and their impact on outcomes.
Fragmented prostate cancer survivorship care is ex-
pensive and associated with potentially unnecessary serv-
ices. Among prostate cancer survivors, highly fragmented
care was found to be > 3 times more costly than the least
fragmented care due, in part, to the greater use of prostate
cancer survivorship interventions. Higher degrees of frag-
mentation were also associated with increased rates of re-
petitive PSA testing within 30 days. Efforts to improve
care coordination via current policy initiatives, electronic
medical records, and the implementation of cancer survi-
vorship tools may help to decrease fragmentation of care
and mitigate some of its downstream consequences for
prostate cancer survivors.
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